Your session is about to expire
← Back to Search
Targeted Therapy for Advanced Stage Cancer (TAPUR Trial)
TAPUR Trial Summary
This trial is studying how well different targeted drugs work in treating patients with cancer that has progressed after other treatments and has a genomic variant that makes the tumor respond to the drug.
TAPUR Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTAPUR Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.TAPUR Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer can't be measured or found through scans or exams.I have an advanced or spreading cancer, multiple myeloma, or B cell lymphoma.I have had brain metastases, but no seizures or major changes in my neurological status in the last 3 months.I have a primary brain tumor or cancer that has spread to the lining of my brain.I can swallow and tolerate pills.I have results from a genetic or protein test for my cancer.I am able to get out of my bed or chair and move around.My blood tests for organ function are within normal ranges.My cancer has a genetic profile that may benefit from specific FDA approved drugs in this study.I am 12 years old or older.My cancer has spread to my brain and is getting worse.
- Group 1: Group 6 (mTOR, TSC)
- Group 2: Group 17 (CDKN2A, CDK4, CDK6)
- Group 3: Group 19 (BRCA1/2, PALB2)
- Group 4: Group 22 (ROS1 fusion)
- Group 5: Group 16 (MSI-H, high mutational load and others)
- Group 6: Group 8 (ERBB2)
- Group 7: Group 20 (ERBB2)
- Group 8: Group 21 (BRCA1/2, PALB2, ATM, and others)
- Group 9: Group 23 (NTRK amplification)
- Group 10: Group 25
- Group 11: Group 4 (CDKN2A, CDK4, CDK6)
- Group 12: Group 9 (BRAF V600E/D/K/R)
- Group 13: Group 15 (POLE, POLD1)
- Group 14: Group 13 (RET,VEGFR1/2/3,KIT,PDGFRβ,RAF-1,BRAF)
- Group 15: Group 5 (CSF1R,PDGFR,VEGFR)
- Group 16: Group 14 (BRCA1/2; ATM)
- Group 17: Group 24 (ERBB2)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has this medication been federally sanctioned?
"This is a Phase 2 trial, which means that while there is some safety data, there is no efficacy data. Our team scores the safety of this treatment as a 2."
Can more people still join this research project?
"From what is noted on clinicaltrials.gov, this study appears to be searching for participants at this time. The trial was originally posted on March 14th, 2016 and the most recent update was November 3rd, 2022."
What is the most common purpose of this medication?
"This type of treatment is often used to manage unresectable melanoma. It may also help patients with microsatellite instability high, squamous cell carcinoma, and those at a high risk for cancer recurrence."
Is this a common treatment that has been studied before?
"This intervention was first explored in a 1999 study based in Ospedale di Circolo e Fondazione Macchi. Since that initial research, there have been 1880 completed trials. As of now, 2851 clinical studies are actively recruiting patients; many of these trials are being conducted out of Kettering, Ohio."
How many study participants are included in this research?
"Correct. Data hosted on clinicaltrials.gov indicates that this medical study, which was first posted on March 14th 2016, is actively recruiting patients. 3641 individuals are needed for the trial at 100 different sites."
Where can people go to participate in this research?
"With 100 locations taking part in this clinical trial, there are plenty of opportunities for patients to get involved. Some notable places include Kettering Health in Kettering, The Queen's Medical Center (The University of Texas MD Anderson Cancer Center) in Honolulu, and Cancer Treatment Centers of America-Phoenix in Phoenix."
Share this study with friends
Copy Link
Messenger